Le Lézard
Classified in: Health
Subjects: AWD, NPT, STP, AVO

New Jersey Senate to honor Partnership for a Drug-Free New Jersey Chair Elaine Pozycki


TRENTON, N.J., June 21, 2018 /PRNewswire-USNewswire/ -- The New Jersey Senate will be honoring Elaine Pozycki for her leadership in addressing New Jersey's opioid epidemic by presenting a resolution at 2 p.m. today at the Statehouse.

Partnership for a Drug-Free New Jersey Co-Chair Elaine Pozycki will be honored with a resolution by the New Jersey Senate for her leadership in combating New Jersey's opioid crisis.

Elaine, co-chair of the Partnership for a Drug-Free New Jersey, spearheaded the legislative efforts in New Jersey that resulted in the patient notification law, passed in February 2017, that now requires all New Jersey practitioners, prior to prescribing an opioid, to have a conversation with their patients on the addictive nature of the medications, as well possible non-opioid alternatives that are available.

The law also requires physicians, physician assistants, dentists and optometrists to complete one Continuing Medical Education credit on topics that include responsible prescribing practices, as well as risks and signs of opioid abuse, addiction and diversion.

"I am humbled and honored to receive this recognition and especially want to thank Senator Vitale and all the members of the New Jersey Senate for their support in the passage of the patient notification legislation that is saving lives every day in our state and nation," Pozycki said.

Realizing the need for the law to be enacted throughout the United States, Elaine and her husband, Steven, launched a national campaign called Prevent Opioid Abuse.

Versions of this groundbreaking legislation have now been adopted in five additional states (Rhode Island, Connecticut, Maryland, Nevada and Michigan) and are being considered by dozens of other state legislatures for adoption.

Best known for its statewide substance use prevention advertising campaign, the Partnership for a Drug-Free New Jersey is a private not-for-profit coalition of professionals from the communications, corporate and government communities whose collective mission is to reduce demand for illicit drugs in New Jersey through media communication. To date, more than $100 million in broadcast time and print space has been donated to the Partnership's New Jersey campaign, making it the largest public service advertising campaign in New Jersey's history. Since its inception the Partnership has garnered 166 advertising and public relations awards from national, regional and statewide media organizations.

SOURCE Partnership for a Drug-Free New Jersey


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: